Kyowa Kirin Pays $100M Upfront to BridgeBio for Skeletal Dysplasias Drug in Japan
Kyowa Kirin’s dealmaking continued on Wednesday when BridgeBio Pharma granted the Japanese company an exclusive license to develop and commercialize infigratinib.
Kyowa Kirin Pays $100M Upfront to BridgeBio for Skeletal Dysplasias Drug in Japan Read More »
